CN112823028A - 用于放射性标记外源性和内源性白蛋白的成像剂 - Google Patents

用于放射性标记外源性和内源性白蛋白的成像剂 Download PDF

Info

Publication number
CN112823028A
CN112823028A CN201980048717.4A CN201980048717A CN112823028A CN 112823028 A CN112823028 A CN 112823028A CN 201980048717 A CN201980048717 A CN 201980048717A CN 112823028 A CN112823028 A CN 112823028A
Authority
CN
China
Prior art keywords
optionally substituted
group
metal complex
cancer
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980048717.4A
Other languages
English (en)
Chinese (zh)
Inventor
F·克瑞兹
K·阿布阿贾
A·华尼克
F·I·诺曼
S·D·科斯特
J·加西亚费尔南德斯
L·派斯
S·达姆
J·P·马格纽森
S·切尔切贾
P·佩雷斯加兰
F·麦达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sentorian Biopharmaceutical Co
Original Assignee
Sentorian Biopharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sentorian Biopharmaceutical Co filed Critical Sentorian Biopharmaceutical Co
Publication of CN112823028A publication Critical patent/CN112823028A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201980048717.4A 2018-07-23 2019-07-16 用于放射性标记外源性和内源性白蛋白的成像剂 Pending CN112823028A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862702081P 2018-07-23 2018-07-23
US62/702,081 2018-07-23
PCT/US2019/042025 WO2020023247A1 (en) 2018-07-23 2019-07-16 Imaging agents for radiolabeling exogenous and endogenous albumin

Publications (1)

Publication Number Publication Date
CN112823028A true CN112823028A (zh) 2021-05-18

Family

ID=69181921

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980048717.4A Pending CN112823028A (zh) 2018-07-23 2019-07-16 用于放射性标记外源性和内源性白蛋白的成像剂

Country Status (11)

Country Link
US (1) US20210353783A1 (https=)
EP (1) EP3826685A4 (https=)
JP (1) JP7395194B2 (https=)
KR (1) KR20210035213A (https=)
CN (1) CN112823028A (https=)
AU (1) AU2019309242B2 (https=)
BR (1) BR112021001314A2 (https=)
CA (1) CA3107328A1 (https=)
IL (1) IL280308B2 (https=)
MX (1) MX2021000926A (https=)
WO (1) WO2020023247A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3263646A1 (en) * 2022-07-29 2024-07-18 Curium Us Llc [177lu] lutetium-psma l&t composition, kit, method of making, and method of using thereof
AU2024317528A1 (en) 2023-07-31 2026-03-05 Curium Us Llc [177 lu] lutetium-psma it composition and dosimetry, kit, method of making, and method of using thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008074960A2 (fr) * 2006-12-14 2008-06-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux conjugues, utilisables a des fins therapeutiques, et/ou a titre d'agent de diagnostic et/ou d'imagerie et leur procede de preparation
US20150023912A1 (en) * 2012-02-21 2015-01-22 Ktb Tumorforschungsgesellschaft Mbh Combinations of albumin-based drug delivery systems

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5094950A (en) * 1988-06-07 1992-03-10 Nihon Medi-Physics Co., Ltd. Diethylenetriamine pentaacetic acid derivatives
US20050233307A1 (en) * 2002-09-12 2005-10-20 Kyle Gee Site-specific labeling of affinity tags in fusion proteins
US20040208828A1 (en) * 2003-02-04 2004-10-21 Lutz Lehmann Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic acid and derivatives thereof, process for their production and use for the production of pharmaceutical agents
DE10305463A1 (de) * 2003-02-04 2004-08-12 Schering Ag Enantiomerenreines (4S,8S)- und (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triza-3N,6N,9N-tricarboxymethyl-1,11-undecandisäure und deren Abkömmlinge, Verfahren zu deren Herstellung und Verwendung zur Herstellung pharmazeutischer Mittel
KR100695744B1 (ko) * 2005-05-03 2007-03-19 한국원자력연구소 디티피에이(ｄｔｐａ) 유도체 및 이들을 이용한 금속 착화물, 이들을 포함하는 방사선원 및 조영제
WO2008070384A2 (en) * 2006-11-06 2008-06-12 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of preparing macromolecular contrast agents and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008074960A2 (fr) * 2006-12-14 2008-06-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux conjugues, utilisables a des fins therapeutiques, et/ou a titre d'agent de diagnostic et/ou d'imagerie et leur procede de preparation
US20150023912A1 (en) * 2012-02-21 2015-01-22 Ktb Tumorforschungsgesellschaft Mbh Combinations of albumin-based drug delivery systems

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NORIHIRO KOBAYASHI ET AL: "Toward in Vivo Imaging of Heart Disease Using a Radiolabeled Single-Chain Fv Fragment Targeting Tenascin-C", 《ANALYTICAL CHEMISTRY》 *

Also Published As

Publication number Publication date
EP3826685A4 (en) 2022-04-06
MX2021000926A (es) 2021-03-31
JP2021532123A (ja) 2021-11-25
JP7395194B2 (ja) 2023-12-11
EP3826685A1 (en) 2021-06-02
WO2020023247A1 (en) 2020-01-30
IL280308B2 (en) 2024-09-01
KR20210035213A (ko) 2021-03-31
AU2019309242A1 (en) 2021-03-11
BR112021001314A2 (pt) 2021-05-11
US20210353783A1 (en) 2021-11-18
CA3107328A1 (en) 2020-01-30
IL280308A (en) 2021-03-01
AU2019309242B2 (en) 2025-05-29
IL280308B1 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
EP3755321B1 (en) Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer
ES2844586T3 (es) Inhibidores del antígeno prostático específico de membrana (PSMA) etiquetados con 18F y su uso como agentes de obtención de imágenes para el cáncer de próstata
ES2990974T3 (es) Conjugados de folato de entidades fijadoras de albúmina
JP2019218351A (ja) 前立腺特異的膜抗原（ｐｓｍａ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用
ES2675320T3 (es) Dendrímeros dirigidos a PSMA
ES2736134T3 (es) Derivado peptídico de tiourea, compuesto marcado con radioisótopos que contiene el mismo y composición farmacéutica que contiene el mismo como ingrediente activo para tratar o diagnosticar el cáncer de próstata
ES2703627T3 (es) Análogos de folato/antifolato marcados con 18F
KR20120047263A (ko) ε­폴리라이신 결합체 및 이의 용도
EP3209336A1 (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CN113164615A (zh) 用于治疗和成像的树状聚体
US20250025582A1 (en) Ligands and their use
EP3672615B1 (en) Fbsa-based therapeutic and radioimaging conjugates targeting carbonic anhydrase positive cancers
US11191778B2 (en) Multifunctional linker technology containing an N4 group
JP7395194B2 (ja) 外因性および内因性アルブミンを放射性標識するためのイメージング剤
CN103732563B (zh) 18f-糖-叶酸类
CA2978304A1 (en) Methods of treating cancer with a psma ligand-tubulysin compound
RU2819907C2 (ru) Средства визуализации для меченного радиоактивным изотопом экзогенного и эндогенного альбумина
CN121909051A (zh) 靶向成纤维细胞活化蛋白的组合物及其使用方法
WO2012153253A2 (en) Aromatic compounds and metal complexes thereof
AU2024311572A1 (en) Fap-targeting compound, and radionuclide-labeled complex based thereon, and preparation method therefor and use thereof
CN104321083B (zh) 用于成像和治疗的亚乙双半胱氨酸‑糖缀合物的有效合成
JP2024518097A (ja) 刷子縁膜酵素切断可能リンカーを持つ葉酸受容体標的コンジュゲート並びにガンのイメージング及び治療における使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20210518

RJ01 Rejection of invention patent application after publication